Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Shigella4V2 Vaccine in 9-month-old Infants
NCT06523231Phase 2Completed
- Sponsor
- LimmaTech Biologics
- Start
- Apr 2025
- Primary completion
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Shigella4V in shigellosis, sponsored by LimmaTech Biologics. Started Apr 2025; status: completed.
02
Drugs
Shigella4V
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT06523231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06523231.